Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Biotechnology

Healthcare
$23.40 +0.05%

+$0.02 today

Market cap
$1.12B
Beta
0.98
P/E (TTM)
-16.2
EPS (TTM)
-$2.27
52W Low $10.51High $42.27

Volume 0.73M

Average 0.33M

RAPP EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$23.99M, compared with -$26.86M a year earlier. Trailing-twelve-month EBITDA was -$118.15M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 10 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -60.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.99M+37.3% QoQ
Last fiscal yearDec 2025
-$124.08M-60.2% YoY
LTMMar 2026
-$118.15M-28.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.7%+100.0%+89.3 pp
1 year-60.2%+100.0%+160.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(124.08M) USD
Year-over-year change
-60.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RAPP compares with its peers on the latest reported figures

  • RAPP's LTM Mar 2026 EBITDA of -$118.15M is the 6th highest of the 10 companies compared; the peer median is -$71.29M.
  • Its year-over-year change of -28.2% is the 7th highest of 9, against a peer median of -6.0%.
  • EBITDA amounts to 590.7% of revenue for RAPP, versus a peer median of 17.2%.
RAPP Competitors Peer median
EBITDA for RAPP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$140.29M +5.0%—11.7%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.31M +41.5%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$39.05M ———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$58.12M -17.3%——
ANROAlto Neuroscience, Inc.LTM Mar 2026-$71.29M -16.9%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-$118.15M -28.2%—590.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-$176.13M +22.9%—22.7%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$198.91M -147.8%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$217.64M +15.4%——
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$359.29M -31.7%——
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding RAPP) -$71.29M-6.0%—17.2%

Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue15K112K839K1.02M
Gross Profit(15K)(112K)(839K)(1.02M)
Gross Margin————
Research & Development9.12M28M60.94M94.79M
Selling, General & Admin1.37M8.07M22.12M30.31M
Operating Expenses10.35M36.07M82.22M125.1M
Depreciation & Amortization15K112K839K1.02M
EBITDA(10.35M)(34.66M)(77.47M)(124.08M)
EBITDA Margin————
Operating Income(10.37M)(36.18M)(83.06M)(125.1M)
Operating Margin————
Interest Income02.53M12.14M13.62M
Interest Expense285K000
Other Income / Expenses(285K)1.4M4.75M13.62M
Income Before Tax(10.65M)(34.78M)(78.31M)(111.48M)
Pre-Tax Margin————
Income Tax Expense010K00
Net Income(10.65M)(34.79M)(78.31M)(111.48M)
Net Margin————
EPS (Basic)(0.29)(0.95)(3.78)(2.86)
EPS (Diluted)(0.29)(0.95)(3.78)(2.86)
Weighted Avg Shares20.12M18.08M20.74M46.98M
Weighted Avg Shares (Diluted)20.12M18.08M20.74M46.98M

Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Intrinsic Alpha fair value

Locked

Current Price

$23.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.